TABLE 1.
Antifungal susceptibility of fluconazole, posaconazole, caspofungin, and a posaconazole-caspofungin combination against clinical isolates of C. glabrata at 48 ha
| Isolate type | Fluconazole susceptibilty, n (%) | MIC50/MIC90 (μg/ml) for:
|
FICIcat, n (%)
|
|||
|---|---|---|---|---|---|---|
| CSP | POS | Antagonism | Indifference | Synergy | ||
| R | 26 (22) | 1/2 | 2/4 | 0 | 25 (96) | 1 (4) |
| S-DD | 33 (28) | 1/2 | 0.5/2 | 0 | 29 (88) | 4 (12) |
| S | 60 (50) | 1/2 | 0.5/2 | 0 | 44 (73) | 16 (27) |
| Total | 119 (100) | 0 (0) | 98 (82) | 21 (18) | ||
a
CSP, caspofungin; POS, posaconazole; FICIcat, fractional inhibitory concentration index interpretive category; R, isolates resistant to fluconazole (MIC ≥ 64 μg/ml); S-DD, isolates that showed dose-dependent susceptibility to fluconazole; S, isolates susceptible to fluconazole.